Patient age influences response to immunotherapy for melanoma

Source: Healio, October 2018

Age should be a consideration when predicting response to immunotherapy for melanoma, according to study results published in Clinical Cancer Research.

Patients aged older than 60 years responded more efficiently to immunotherapy, even in the absence of an involved mutational landscape.

Ashani Weeraratna, PhD, Ira Brind professor and co-program leader of the immunology, microenvironment and metastasis Program at The Wistar Institute, and colleagues assessed the association between age and immunotherapy response among 538 patients with melanoma treated with the anti-PD1 therapy pembrolizumab (Keytruda, Merck).

Menu